The 2019 Drug Pricing and Reimbursement Stakeholder Summit examines the current and future changes to the pricing landscape as it shifts in response to administrative changes.
Given federal and state pricing requirements arising, press releases from industry leading pharma companies, and the new Drug Transparency Act, it is important to stay ahead of news headlines and anticipated requirements in order to hit company profit targets, maintain value to patients and promote strong, multi-beneficial relationships with manufacturers, providers, payers, and all other stakeholders within the pricing landscape.
This conference will provide a platform to encourage a dialogue among such stakeholders in the pricing and reimbursement space so that they can receive a current state of the union regarding regulatory changes while providing actionable insights in anticipation of the future.
Life Science/Service Providers - Early Bird Pricing - Register by June 7: USD 1795.0,
Payers/Health Systems - Early Bird Pricing - Register by June 7: USD 1395.0,
Life Science/Service Providers - Standard Pricing - Register after June 7: USD 1995.0,
Payers/Health Systems - Standard Pricing - Register after June 7: USD 1595.0,
Life Science/Service Providers - Onsite Pricing: USD 2095.0,
Payers/Health Systems - Onsite Pricing: USD 1695.0
Speakers: John Alter, VP, Patient and Health Impact Lead, Hospital Business Unit, PFIZER, Kendra Martello, Senior Director, Public Policy, MALLINCKRODT PHARMACEUTICALS, Deborah Walters, Vice President and Assistant General Counsel, PFIZER, Mallory O'Connor, Director, Healthcare Policy and Federal Programs, BIOTECHNOLOGY INNOVATION ORGANIZATION- BIO, Boxiong Tang, Senior Director, BEIGENE